CT Perfusion and CT Angiography Not Useful as Standalone Tests for Establishing Death by Neurologic Criteria
THURDAY, June 26, 2025 -- Neither computed tomography (CT) perfusion nor CT angiography meet the prespecified validation threshold as an ancillary test for death by neurologic criteria (DNC) in critically ill patients, according to a study published online June 13 in JAMA Neurology to coincide with the annual Critical Care Reviews Meeting, held from June 11 to 13 in Belfast, Northern Ireland.
Michaël Chassé, M.D., Ph.D., from the Université de Montréal, and colleagues examined the diagnostic accuracy, interrater reliability, and safety of brain CT perfusion and CT angiography as ancillary investigations for DNC in a prospective, multicenter cohort study conducted in 15 adult intensive care units. Consecutive, critically ill adults with a Glasgow Coma Scale score of 3, who were at high risk of DNC, were included.
The primary analysis included 282 patients; 72 percent were ultimately declared deceased by standardized clinical criteria. The researchers found that qualitative brainstem CT perfusion showed sensitivity and specificity of 98.5 and 74.4 percent, respectively; quantitative brainstem CT perfusion was not diagnostically accurate. Qualitative whole-brain CT perfusion yielded a sensitivity and specificity of 93.6 and 92.3 percent, respectively. The sensitivity of CT angiography ranged from 75.5 to 87.3 percent, and specificity varied from 89.7 to 91.0 percent. For all ancillary tests, interrater reliability was excellent (κ ranged from 0.81 to 0.84). Minor, self-limited adverse events occurred in 14 patients; there were no serious adverse events.
"Neither CT perfusion nor CT angiography met the prespecified threshold of greater than 98 percent for both sensitivity and specificity. Consequently, they should not be used as standalone tests to establish DNC," the authors write.
Several authors disclosed ties to industry; one author reported having multiple related patents.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Cancer Survival Lower in Rural Areas
WEDNESDAY, Oct. 1, 2025 -- Five-year cancer survival rates for each stage of cancer (localized, regional, and distant) is lower in nonmetropolitan areas for Black and White...
Loss of Smell May Linger After COVID-19
WEDNESDAY, Oct. 1, 2025 -- Self-reported change or loss in smell or taste is an accurate signal of verified hyposmia after COVID-19, although there is also a high rate of hyposmia...
Elderly Patients Benefit From Screening Mammography
WEDNESDAY, Oct. 1, 2025 -- Patients with breast cancer diagnosed at 80 years of age or older who received screening mammography present with earlier-stage disease and have better...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.